QT interval variability in familial Mediterranean fever: a study in colchicine-responsive and colchicine-resistant patients

被引:14
作者
Nussinovitch, Udi [1 ]
Kaminer, Keren [2 ]
Nussinovitch, Moshe [2 ,3 ]
Volovitz, Benjamin [2 ,3 ]
Lidar, Merav [2 ,4 ,6 ]
Nussinovitch, Naomi [2 ,5 ,7 ]
Livneh, Avi [2 ,4 ,6 ]
机构
[1] IDF Med Corps, Israel Naval Med Inst, IL-31080 Haifa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Schneider Childrens Med Ctr Israel, Dept Pediat C, Petah Tiqwa, Israel
[4] Chaim Sheba Med Ctr, Heller Inst Med Res, IL-52621 Tel Hashomer, Israel
[5] Chaim Sheba Med Ctr, Hypertens Unit, IL-52621 Tel Hashomer, Israel
[6] Chaim Sheba Med Ctr, Dept Med F, IL-52621 Tel Hashomer, Israel
[7] Chaim Sheba Med Ctr, Dept Internal Med D, IL-52621 Tel Hashomer, Israel
关键词
Arrhythmia; Familial Mediterranean fever; QT dispersion (QTd); QT variability index (QTVI); DISPERSION; ATHEROSCLEROSIS; REPOLARIZATION; DIAGNOSIS; DISEASE;
D O I
10.1007/s10067-011-1926-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The association between familial Mediterranean fever (FMF), early atherosclerosis, and electrocardiographic markers for arrhythmias remains controversial. There are conflicting results as to the occurrence of high QT dispersion in FMF. The aim of the present study was to further investigate repolarization dynamics and other repolarization-associated pro-arrhythmogenic markers in FMF patients. To explore repolarization in FMF, patients who responded well to colchicine and patients who had not responded to colchicine, yet were amyloidosis-free, were included. We aimed to evaluate whether increased inflammatory burden, a characteristic of non-responsive patients, was specifically associated with abnormal repolarization. Included in the study were 53 FMF patients (27 colchicine non-responders) and 53 age- and sex-matched control subjects. Electrocardiograms were performed under strict standards. QT variability parameters were computed with custom-made computer software. No significant difference in any of the QT dynamic parameters was found in either FMF group compared with the healthy controls. Mean values of QT variability index, regardless of colchicine response, were similar to previously published results for healthy persons. In conclusion, patients with FMF who are continuously treated with colchicine and have not developed amyloidosis, regardless of their clinical response, have normal QT variability parameters, indicating normal repolarization dynamics and suggesting no increased risk of repolarization-associated cardiac arrhythmias.
引用
收藏
页码:795 / 799
页数:5
相关论文
共 50 条
  • [31] Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review
    Karadeniz, Hazan
    Guler, Aslihan Avanoglu
    Atas, Nuh
    Satis, Hasan
    Salman, Reyhan Bilici
    Babaoglu, Hakan
    Tufan, Abdurrahman
    RHEUMATOLOGY INTERNATIONAL, 2020, 40 (01) : 169 - 173
  • [32] Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review
    Hazan Karadeniz
    Aslıhan Avanoğlu Güler
    Nuh Atas
    Hasan Satış
    Reyhan Bilici Salman
    Hakan Babaoglu
    Abdurrahman Tufan
    Rheumatology International, 2020, 40 : 169 - 173
  • [33] Efficacy of anti-interleukin-1 treatment in colchicine-resistant arthritis in patients with familial Mediterranean fever
    Kehribar, Demet Yalcin
    Ozgen, Metin
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2021, 8 (01) : 16 - 19
  • [34] Factors Associated With Successful Withdrawal of Biologic Agents in Children With Colchicine-Resistant Familial Mediterranean Fever
    Tas, Ozen
    Aydin, Fatma
    Sezer, Muge
    Acar, Banu Celikel
    Bahceci, Onur
    Cakar, Nilgun
    Dumlupinar, Ebru
    Ozcakar, Zeynep Birsin
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2024, 30 (07) : 257 - 263
  • [35] Efficacy and safety of anti-interleukin-1 in children with colchicine-resistant familial Mediterranean fever
    Erkilet, Hatice Kubra
    Yildirim, Deniz Gezgin
    Esmeray, Pelin
    Soylemezoglu, Oguz
    PEDIATRICS INTERNATIONAL, 2023, 65 (01)
  • [36] Diagnostic validity of colchicine in patients with Familial Mediterranean fever
    Ozaltin, Fatih
    Bilginer, Yelda
    Gulhan, Bora
    Bajin, Inci
    Erdogan, Ozlem
    Hayran, Mutlu
    Yilmaz, Engin
    Ozen, Seza
    CLINICAL RHEUMATOLOGY, 2014, 33 (07) : 969 - 974
  • [37] Diagnostic validity of colchicine in patients with Familial Mediterranean fever
    Fatih Ozaltin
    Yelda Bilginer
    Bora Gülhan
    Inci Bajin
    Ozlem Erdogan
    Mutlu Hayran
    Engin Yılmaz
    Seza Ozen
    Clinical Rheumatology, 2014, 33 : 969 - 974
  • [38] Total Hip Joint Replacement in a Patient with Colchicine-Resistant Familial Mediterranean Fever under Canakinumab Treatment
    Matsumoto, Haruki
    Ohashi, Hironori
    Fujita, Yuya
    Yoshida, Shuhei
    Yokose, Kohei
    Temmoku, Jumpei
    Matsuoka, Naoki
    Shinden, Yumetaka
    Kusano, Keigo
    Sonobe, Tatsuru
    Nakamoto, Yohei
    Yashiro-Furuya, Makiko
    Asano, Tomoyuki
    Sato, Shuzo
    Suzuki, Eiji
    Yago, Toru
    Watanabe, Hiroshi
    Migita, Kiyoshi
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2022, 256 (02) : 169 - 174
  • [39] Colchicine-responsive chronic recurrent multifocal osteomyelitis associated with familial Mediterranean fever in the presence of MEFV mutation: A case report
    Izumikawa, Miharu
    Kato, Mikiya
    Wakiya, Risa
    Kameda, Tomohiro
    Nakashima, Shusaku
    Shimada, Hiromi
    Miyagi, Taichi
    Sugihara, Koichi
    Ushio, Yusuke
    Mino, Rina
    Mizusaki, Mao
    Chujo, Kanako
    Hiraishi, Takashi
    Kadowaki, Norimitsu
    Dobashi, Hiroaki
    MODERN RHEUMATOLOGY CASE REPORTS, 2023, 8 (01) : 195 - 198
  • [40] Therapeutic approach to patients with familial Mediterranean fever-related amyloidosis resistant to colchicine
    Korkmaz, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (03) : S104 - S107